News Releases

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
PDF Version
Read More
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 8, 2026
PDF Version
Read More
CAMP4 to Participate in Upcoming Investor Conferences
September 1, 2026
PDF Version
Read More
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights  
August 13, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 4, 2026
PDF Version
Read More
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
PDF Version
Read More
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
PDF Version
Read More
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
PDF Version
Read More